History
  • No items yet
midpage
ALTANA PHARMA AG v. TEVA PHARMACEUTICALS USA INC
2:04-cv-02355
D.N.J.
May 14, 2013
Read the full case

Background

  • United States District Court for the District of New Jersey; Altana Pharma AG and Wyeth sue Teva over pantoprazole patents and damages theories.
  • Teva moves to exclude Dr. Christopher Vellturo's damages opinions (price erosion, lost profits, lost royalties, reasonable royalties) and Dr. Jeffrey Leitzinger's opinions on Sun liability for lost profits.
  • Vellturo’s damages framework includes lost profits on lost sales, price erosion on retained sales, and a reasonable royalty for expansion and overall infringing sales; alternative total damages are proposed.
  • Leitzinger contends that Sun's liability for lost profits should reflect that other infringers (and Wyeth’s own generic) were already in the market; he critiques Vellturo’s calculations.
  • Court denies Teva's motion in part and grants in part: price erosion and reasonable royalties opinions by Vellturo are allowed; Nycomed lost profits on lost sales are excluded; Leitzinger may opine on Sun’s liability only to the extent tied to attribution to Wyeth’s own generic rather than Sun’s infringing product.
  • Order issued May 2013.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Admissibility of Vellturo's price erosion opinion Plaintiffs. Teva. Not excluded; admissible.
Admissibility of Vellturo's reasonable royalty opinion Plaintiffs. Teva. Not excluded; admissible.
Nycomed lost profits on lost sales Nycomed seeks lost profits. Court previously barred lost profits; focus on royalties. Lost profits on lost sales excluded; lost royalties potentially admissible.
Leitzinger's testimony on Sun's liability for lost profits Sun liable for lost profits. Sun's liability contested; apportionment allowed. Teva's motion granted to the extent opposing Sun’s liability; Sun may attribute some lost sales to Wyeth's generic.

Key Cases Cited

  • Radio Steel & Mfg. Co. v. MTD Prods., Inc., 788 F.2d 1554 (Fed. Cir. 1986) (reasonable royalty framework at time of infringement)
  • Georgia-Pacific Corp. v. U.S. Plywood Corp., 318 F. Supp. 1116 (S.D.N.Y. 1970) (15 factors for determining reasonable royalty; framework endorsed)
  • LaserDynamics, Inc. v. Quanta Computer, Inc., 694 F.3d 51 (Fed. Cir. 2012) (Georgia-Pacific factors sanctioned in modern practice)
  • Oddi v. Ford Motor Co., 234 F.3d 136 (3d Cir. 2000) (gatekeeping and reliability standard for expert testimony)
  • ZF Meritor, LLC v. Eaton Corp., 696 F.3d 254 (3d Cir. 2012) (reliability and fit under Rule 702; data–driven analysis)
  • Paoli R.R. Yard PCB Litig., 35 F.3d 717 (3d Cir. 1994) (liberal qualification standard for experts; Daubert gatekeeping)
  • Mars, Inc. v. Coin Acceptors, Inc., 527 F.3d 1359 (Fed. Cir. 2008) (royalty framework may involve infringer’s profit; possible losses)
Read the full case

Case Details

Case Name: ALTANA PHARMA AG v. TEVA PHARMACEUTICALS USA INC
Court Name: District Court, D. New Jersey
Date Published: May 14, 2013
Docket Number: 2:04-cv-02355
Court Abbreviation: D.N.J.